Small cell carcinoma of gastro-oesophageal junction with remarkable response to chemo-radiotherapy.

BMJ Case Rep

Department of Medical Oncology, International Medical Center, Comprehensive Cancer Center, Saitama Medical University, Hidaka, Japan.

Published: July 2012

AI Article Synopsis

  • Small cell carcinoma in the gastrointestinal tract is rare, and effective treatment strategies are still not well-established.
  • Researchers administered chemotherapy (cisplatin plus etoposide) and radiotherapy to relieve blockage in a patient with small cell carcinoma of the gastro-oesophageal junction, then switched to carboplatin plus etoposide due to kidney issues.
  • The patient showed a complete response with no recurrence for over a year, suggesting that carboplatin may be a viable alternative when cisplatin isn't suitable due to renal toxicity.

Article Abstract

Small cell carcinoma of the gastrointestinal tract is rare, and no effective strategy has yet been established. On the basis of regimens reportedly effective for small cell lung cancer, we performed chemotherapy with cisplatin plus etoposide in combination with radiotherapy to relieve obstruction, in a patient with small cell carcinoma of the gastro-oesophageal junction. Chemotherapy was switched to carboplatin plus etoposide due to renal toxicity. No distant metastases were detected and lesion spread was limited. A complete response, with no evidence of recurrence to date, was achieved. Curative resection was suggested but refused by the patient. He has been closely followed up in our outpatient clinic for more than a year and has shown no evidence of recurrence since the completion of treatment. Although cisplatin plus etoposide is a standard chemotherapy regimen for small cell carcinoma, carboplatin plus etoposide may be effective in cases in which cisplatin is contraindicated due to renal toxicity.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4543306PMC
http://dx.doi.org/10.1136/bcr-2012-006361DOI Listing

Publication Analysis

Top Keywords

small cell
20
cell carcinoma
16
carcinoma gastro-oesophageal
8
gastro-oesophageal junction
8
cisplatin etoposide
8
carboplatin etoposide
8
renal toxicity
8
evidence recurrence
8
small
5
carcinoma
4

Similar Publications

Objective: Pulmonary pleomorphic carcinoma is a relatively rare and aggressive subtype of non-small cell lung cancer (NSCLC), with a poor prognosis and early recurrence, and is resistant to conventional therapies. This study investigated the efficacy of immune checkpoint inhibitors (ICIs) in improving the survival outcomes of patients with pulmonary pleomorphic carcinoma with postoperative recurrence.

Methods: We conducted a retrospective analysis of 71 patients with pulmonary pleomorphic carcinoma who underwent pulmonary resection at Tokyo Medical University Hospital between 2008 and 2022.

View Article and Find Full Text PDF

Attachment of Hydrogel Patches to Eye Tissue through Gel Transfer using Flexible Foils.

ACS Appl Mater Interfaces

January 2025

Department of Microsystems Engineering (IMTEK), Laboratory for Chemistry & Physics of Interfaces (CPI), Albert Ludwigs Universität Freiburg, Georges Köhler Allee 103, 79110 Freiburg, Germany.

Glaucoma, a leading cause of blindness, demands innovative and effective treatments that surpass the limitations of current drug and surgical interventions to lower intraocular pressure. This study describes the generation of cell-repellent hydrogel patches, their deposition on the ocular surface, and a photoinduced chemical binding between the patches and the collagens of the eye. The hydrophilic and protein-repellent hydrogel patch is composed of a copolymer made from dimethylacrylamide and a comonomer unit with anthraquinone moieties.

View Article and Find Full Text PDF

Hepatosplenic T-cell lymphoma in children and adolescents.

Blood Adv

January 2025

Univeristy of Alabama at Birmingham, Birmingham, Alabama, United States.

Hepatosplenic T-cell lymphoma (HSTCL) is an aggressive mature T-cell lymphoma characterized by significant hepatosplenomegaly, bone marrow involvement, and minimal or no lymphadenopathy. Primarily affecting young adults, it is exceptionally rare in children and adolescents. This makes diagnosis and treatment particularly challenging for pathologists and pediatric oncologists.

View Article and Find Full Text PDF

Antigen receptor ITAMs provide tonic signaling by acting as guanine nucleotide exchange factors to directly activate R-RAS2.

Sci Signal

January 2025

Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, 28049 Madrid, Spain.

The small GTPase R-RAS2 regulates homeostatic proliferation and survival of T and B lymphocytes and, when present in high amounts, drives the development of B cell chronic lymphocytic leukemia. In normal and leukemic lymphocytes, R-RAS2 constitutively binds to antigen receptors through their immunoreceptor tyrosine-based activation motifs (ITAMs) and promotes tonic activation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway. Here, we examined the molecular mechanisms underlying this direct interaction and its consequences for R-RAS2 activity.

View Article and Find Full Text PDF

Lineage tracing studies suggest that the placenta is not a de novo source of hematopoietic stem cells.

PLoS Biol

January 2025

Cardiovascular Institute and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.

Definitive hematopoietic stem and progenitor cells (HSPCs) arise from a small number of hemogenic endothelial cells (HECs) within the developing embryo. Understanding the origin and ontogeny of HSPCs is of considerable interest and potential therapeutic value. It has been proposed that the murine placenta contains HECs that differentiate into HSPCs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!